Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN)

TheFly reported connected January 22 that Evercore ISI accrued its terms people for REGN to $875 from $750 and maintained an Outperform standing connected the stock. The steadfast expressed assurance successful REGN’s updated outlook and caller pricing actions. Evercore ISI identified Dupixent and Eylea HD arsenic cardinal players successful the company’s maturation and noted that some products are well-positioned to prolong existent competitiveness and amended aboriginal performance.

Similarly, earlier this month, connected January 8, Goldman Sachs besides raised its terms people for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $914 from $807 and gave it a Buy rating. The steadfast cited beardown assemblage show successful 2025 and expects the affirmative momentum to proceed into 2026, which is supported by favorable marketplace conditions, easing argumentation risks, and imaginable M&A activity.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is simply a biotechnology institution specializing successful the discovery, development, and commercialization of innovative medicines for superior diseases.

While we admit the imaginable of REGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.